Use of neuraminidase inhibitors for treatment of severe influenza: Times are changing

Clinical Infectious Diseases

Volumn 64, Issue 3, 2017, Pages 368-369

  Martin, Emily T ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Hospitalization; Influenza; Neuraminidase inhibitors

Indexed keywords

SIALIDASE INHIBITOR; ANTIVIRUS AGENT; ENZYME INHIBITOR; OSELTAMIVIR; SIALIDASE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; EDITORIAL; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA; OUTPATIENT CARE; PRIORITY JOURNAL; TIME TO TREATMENT; ADULT; CHILD; HOSPITALIZED CHILD;

ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, HOSPITALIZED; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR;

EID: 85027775858     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw747     Document Type: Editorial

References (14)

1. Appiah GD, Blanton L, D'Mello T, et al; Centers for Disease Control and Prevention (CDC). Influenza activity-United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep 2015; 64:583-90.
2. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
3. IDSA : IDSA Continues to Recommend Antivirals for Influenza [Internet]. [cited 2016 Oct 25]. Available from: https://www.idsociety.org/Influenza- Statement.aspx. Accessed 25 October 2016.
4. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: A meta-analysis. Ann Intern Med 2012; 156:500-11.
5. McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75.
6. Muthuri SG, Venkatesan S, Myles PR, et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
7. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. Lancet 2015; 385:1729-37.
8. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2545.
9. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2547.
10. Cowling BJ, Ng S, Longini IM Jr. A/H1N1 flu pandemic. Antiviral drugs: distinguish treatment from prophylaxis. BMJ 2009; 339:b3620.
11. Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: A randomised placebo-controlled trial. Lancet Infect Dis 2014; 14:109-18.
12. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2016-2017. Pediatrics. 2016; 138:e20162527.
13. Aoki FY, Macleod MD, Paggiaro P, et al; IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
14. Davlin SL, Blanton L, Kniss K, et al. Influenza activity-United States, 2015-16 season and composition of the 2016-17 influenza vaccine. MMWR Morb Mortal Wkly Rep 2016; 65:567-75.